Vyvgart Hytrulo (CIDP) – Compliance Alert

Caution

This ad has patterns previously flagged by FDA.

Analysis of this 60s ad identified 3 enforcement patterns, primarily Visual Distraction. Patterns span Visual Distraction, Efficacy — “Outdoor & Physical Activity” identified at 30.7s, previously cited in BRUKINSA, COBENFY, Fasenra (x3). FDA enforcement letter on file dated Jan 30, 2026.

Recommended action: Flag for next MLR cycle: Visual content during safety information window (20s–45s) may distract from risk disclosure. Schedule creative revision to use static or neutral visuals during major statement.

Video Timeline

Risk disclosure: 20.2s – 45.3s (25.0s of 60.1s total — 41.7% of ad)

Risk Window

0s15s30s45s60s

Daily Activities?Outdoor & Physical?Risk Window?

Patterns Detected (3)

Each pattern below is a known FDA enforcement concern, identified by matching this ad against 14 violation types from 34 FDA warning letters

Pattern	Dimension	Score	Evidence	CFR
Outdoor & Physical Activity Upbeat outdoor imagery shown while safety warnings are being read	Visual Distraction	43	2 clips	21 CFR 202.1(e)(1)	▶
FDA Concern: Risk information must be presented in a clear, conspicuous, and neutral manner without distracting visuals Previously cited: BRUKINSA, COBENFY, Fasenra (x3), Velsipity, Calquence
Daily Activities Relatable lifestyle visuals that divert attention from safety disclosures	Visual Distraction	43	4 clips	21 CFR 202.1(e)(1)	▶
FDA Concern: Risk information must be presented in a clear, conspicuous, and neutral manner without distracting visuals Previously cited: Contrave, Velsipity, Qulipta, Fasenra (salsa)
Comparative Claims Claims suggesting superiority without adequate supporting data	Efficacy	62	2 clips	21 CFR 202.1(e)(5)	▶
FDA Concern: Advertisements cannot be false or misleading in any particular Previously cited: NEXLIZET, COBENFY

Recommendations

high

Flag for next MLR cycle: Visual content during safety information window (20s–45s) may distract from risk disclosure. Schedule creative revision to use static or neutral visuals during major statement.

high

Initiate PromoMats review: Verify all efficacy claims against current approved labeling. Visual representations should align with clinical trial results referenced in the PI.

high

Escalate to regulatory affairs: FDA enforcement letter on file (Jan 30, 2026). Verify remediation status in PromoMats and confirm all content modifications address cited violations before next distribution.

Compliance Alert: Vyvgart Hytrulo (CIDP)

Recommendations